Reuters logo
BRIEF-Erytech reports positive Phase 2b data for eryaspase
March 27, 2017 / 5:45 AM / 8 months ago

BRIEF-Erytech reports positive Phase 2b data for eryaspase

March 27 (Reuters) - Erytech Pharma SA:

* Erytech reports positive Phase 2b data for Eryaspase for the treatment of metastatic pancreatic cancer

* Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS)

* Statistically significant improvement of OS and pfs in entire patient population

* Announced positive topline results from its phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA)

* Multicenter, randomized Phase 2b study met its prespecified co-primary endpoints Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below